Bartonellosis Global Market Report 2025

The bartonellosis market size has grown rapidly in recent years. It will grow from $1.17 billion in 2024 to $1.31 billion in 2025 at a compound annual growth rate (CAGR) of 12%. The growth during the historic period can be attributed to the rising prevalence of Bartonella disease, increased healthcare expenditure, greater funding for research and development, the growing incidence of transmissible illnesses, and the increasing occurrence of infectious diseases.

The bartonellosis market size is expected to see rapid growth in the next few years. It will grow to $2.03 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth during the forecast period can be attributed to the increasing incidence of zoonotic diseases, rising disease awareness, a growing pet-owning population, a stronger focus on personalized medicine, and greater awareness of cat scratch disease. Key trends expected in this period include advancements in medical technology and biotechnology, the development of combined testing methods, improvements in diagnostic techniques, and continuous research and development efforts.

The increasing prevalence of zoonotic diseases is anticipated to drive the growth of the bartonellosis market in the coming years. Zoonotic diseases are infections transmitted from animals to humans, either directly or via vectors. The surge in zoonotic disease cases can be attributed to factors such as heightened human-animal interactions, environmental changes, deforestation, global travel, and the cross-species spread of pathogens. Bartonellosis serves as a significant example of a bacterial pathogen transmitted through animal vectors such as fleas, ticks, and lice, which can infect humans and cause various clinical manifestations. This underscores the importance of understanding vector-borne disease transmission in public health. For instance, in January 2023, a report published by the Government of Canada, a federal authority, indicated that 159 rabies samples were submitted in November 2022, compared to 135 samples in October 2022. Consequently, the growing incidence of zoonotic diseases is fueling the expansion of the bartonellosis market.

Leading companies in the bartonellosis market are prioritizing fundraising initiatives to enhance early detection and improve treatment options for the disease. These efforts involve organizations raising funds to support research, diagnosis, treatment, and prevention of bartonellosis, thereby fostering innovation and improving access to healthcare solutions. For example, in April 2022, the Global Lyme Alliance (GLA), a US-based nonprofit organization, launched a crowdfunding campaign to raise $300,000 for pioneering research on Bartonella, a hidden pathogen linked to severe health conditions such as neuroinflammation and psychiatric disorders. This initiative coincided with Lyme Disease Awareness Month and aimed to deepen the understanding of Bartonella’s behavior within the body, which is essential for developing more effective treatments for Bartonella infections and related conditions such as Lyme disease. The campaign highlighted the need for greater awareness and funding to assist individuals affected by these debilitating diseases.

In October 2024, R.E.D. Laboratories, a Belgium-based biomedical diagnostic company, collaborated with IGeneX Inc. to broaden access to IGeneX’s advanced testing panels. Through this partnership, customers in Europe, Africa, and the Middle East can directly access IGeneX’s specialized Lyme disease and co-infection tests via RED Labs. IGeneX Inc. is a US-based provider of diagnostic test kits for bartonellosis.

Major players in the bartonellosis market are Mayo Clinic Laboratories, Northwell Health Labs, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, IDEXX Laboratories Inc., Bio-Rad Laboratories Inc., Alberta Precision Laboratories, Jiangsu BioPerfectus Technologies Co. Ltd., ARUP Laboratories, Surmodics Inc., Medical Diagnostic Laboratories LLC, Creative Biolabs, IGeneX Inc., Karius Inc., Synnovis Group LLP, Galaxy Diagnostics Inc., Gold Standard Diagnostics, Eurofins Biomnis, AMMAGENOMICS Private Limited, Ringbio.

North America was the largest region in the bartonellosis market in 2024. The regions covered in bartonellosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bartonellosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bartonellosis is a bacterial infection caused by the Bartonella genus, affecting the skin, lymph nodes, and internal organs. Prompt diagnosis and antibiotic treatment are crucial to prevent severe systemic complications and ensure effective disease management.

The primary forms of bartonellosis include cat scratch disease (CSD), trench fever, Bartonella endocarditis, and others. Cat scratch disease, caused by Bartonella henselae and transmitted through cat scratches or bites, results in symptoms such as swollen lymph nodes, fever, and fatigue. Diagnosis involves various methods, including polymerase chain reaction (PCR) testing, serological testing, culture techniques, and histological examination. Treatment options consist of antibiotics, antibacterial agents, and supportive care. The disease is managed by various end-users, including hospitals and clinics, diagnostic laboratories, and others.

The bartonellosis market research report is one of a series of new reports that provides bartonellosis market statistics, including the bartonellosis industry global market size, regional shares, competitors with the bartonellosis market share, detailed bartonellosis market segments, market trends, and opportunities, and any further data you may need to thrive in the bartonellosis industry. This bartonellosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bartonellosis market consists of revenues earned by entities by providing services such as medical consultation, symptom management, and vector control and prevention. The market value includes the value of related goods sold by the service provider or included within the service offering. The bartonellosis market includes sales of diagnostic kits, preventive products, pain relievers, and immune support supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.